CIK 0001678660
- Non-accelerated filer
- Smaller reporting company
Prelude Therapeutics Inc
Sign in to watch- Ticker
- PRLD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811384762
- Phone
- +1 302-467-1280
- Business address
- 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
- Former names
- Prelude Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-08-21 | BAKER BROS. ADVISORS LP Director | Purchase · Series C Preferred Stock | +75,873 | $14.52 | $1.1M | 75,873 |
| 2020-08-21 | BAKER BROS. ADVISORS LP Director | Purchase · Series C Preferred Stock | +957,211 | $14.52 | $13.9M | 957,211 |
| 2020-08-21 | ORBIMED ADVISORS LLC Director | Purchase · Series C Preferred Stock | +1,033,084 | 1,033,084 | ||
| 2020-08-21 | Bonita David P Director | Purchase · Series C Preferred Stock | +1,033,084 | 1,033,084 | ||
| 2020-03-27 | BAKER BROS. ADVISORS LP Director | Purchase · Series B Preferred Stock | +308,793 | $3.93 | $1.2M | 308,793 |
| 2020-03-27 | BAKER BROS. ADVISORS LP Director | Purchase · Series B Preferred Stock | +3,373,029 | $3.93 | $13.3M | 3,373,029 |
| 2020-03-27 | ORBIMED ADVISORS LLC Director | Purchase · Series B Preferred Stock | +3,681,822 | 7,363,644 | ||
| 2020-03-27 | FRIEDMAN PAUL A Director | Purchase · Series B Preferred Stock | +76,288 | 152,576 | ||
| 2020-03-27 | Bonita David P Director | Purchase · Series B Preferred Stock | +3,681,822 | 7,363,644 |
Page 19 of 19 · 369 trades